Rehabilitative management of post-acute COVID-19: clinical pictures and outcomes
Abstract This study aimed to detect patients’ characteristics who suffered severe and critical COVID-19 pneumonia admitted to the post-acute COVID-19 rehabilitation clinic in Ankara City Hospital, Physical Medicine and Rehabilitation Hospital and to share our experiences and outcomes of rehabilitation programmes applied. This study was designed as a single-centre, retrospective, observational study. Severe and critical COVID-19 patients, admitted to the post-acute COVID-19 rehabilitation clinic, were included in patient-based rehabilitation programmes, targeting neuromuscular and respiratory recovery. Functional status, oxygen ($ O_{2} $) requirement and daily living activities were assessed before and after rehabilitation. Eighty-five patients, of which 74% were male, were analysed, with the mean age of 58.27 ± 11.13 and mean body mass index of 25.29 ± 4.81 kg/$ m^{2} $. The most prevalent comorbidities were hypertension (49.4%) and diabetes mellitus (34.1%). Of the 85 patients, 84 received antiviral drugs, 81 low-molecular-weight heparin, 71 corticosteroids, 11 anakinra, 4 tocilizumab, 16 intravenous immunoglobulin and 6 plasmapheresis. 78.8% of the patients were admitted to the intensive care unit, with a mean length of stay of 19.41 ± 18.99 days, while those who needed $ O_{2} $ support with mechanic ventilation was 36.1%. Neurological complications, including Guillain–Barré syndrome, critical illness-related myopathy/neuropathy, cerebrovascular disease and steroid myopathy, were observed in 39 patients. On initial functional statuses, 55.3% were bedridden, 22.4% in wheelchair level and 20% mobilised with $ O_{2} $ support. After rehabilitation, these ratios were 2.4%, 4.7% and 8.2%, respectively. During admission, 71 (83.5%) patients required $ O_{2} $ support, but decreased to 7 (8.2%) post-rehabilitation. Barthel Index improved statistically from 44.82 ± 27.31 to 88.47 ± 17.56. Patient-based modulated rehabilitation programmes are highly effective in severe and critical COVID-19 complications, providing satisfactory well-being in daily living activities..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Rheumatology international - 41(2021), 12 vom: 27. Sept., Seite 2167-2175 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Güler, Tuba [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
COVID-19 |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
---|
doi: |
10.1007/s00296-021-05003-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR045397732 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR045397732 | ||
003 | DE-627 | ||
005 | 20230519134018.0 | ||
007 | cr uuu---uuuuu | ||
008 | 211027s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00296-021-05003-1 |2 doi | |
035 | |a (DE-627)SPR045397732 | ||
035 | |a (SPR)s00296-021-05003-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.83 |2 bkl | ||
100 | 1 | |a Güler, Tuba |e verfasserin |4 aut | |
245 | 1 | 0 | |a Rehabilitative management of post-acute COVID-19: clinical pictures and outcomes |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
520 | |a Abstract This study aimed to detect patients’ characteristics who suffered severe and critical COVID-19 pneumonia admitted to the post-acute COVID-19 rehabilitation clinic in Ankara City Hospital, Physical Medicine and Rehabilitation Hospital and to share our experiences and outcomes of rehabilitation programmes applied. This study was designed as a single-centre, retrospective, observational study. Severe and critical COVID-19 patients, admitted to the post-acute COVID-19 rehabilitation clinic, were included in patient-based rehabilitation programmes, targeting neuromuscular and respiratory recovery. Functional status, oxygen ($ O_{2} $) requirement and daily living activities were assessed before and after rehabilitation. Eighty-five patients, of which 74% were male, were analysed, with the mean age of 58.27 ± 11.13 and mean body mass index of 25.29 ± 4.81 kg/$ m^{2} $. The most prevalent comorbidities were hypertension (49.4%) and diabetes mellitus (34.1%). Of the 85 patients, 84 received antiviral drugs, 81 low-molecular-weight heparin, 71 corticosteroids, 11 anakinra, 4 tocilizumab, 16 intravenous immunoglobulin and 6 plasmapheresis. 78.8% of the patients were admitted to the intensive care unit, with a mean length of stay of 19.41 ± 18.99 days, while those who needed $ O_{2} $ support with mechanic ventilation was 36.1%. Neurological complications, including Guillain–Barré syndrome, critical illness-related myopathy/neuropathy, cerebrovascular disease and steroid myopathy, were observed in 39 patients. On initial functional statuses, 55.3% were bedridden, 22.4% in wheelchair level and 20% mobilised with $ O_{2} $ support. After rehabilitation, these ratios were 2.4%, 4.7% and 8.2%, respectively. During admission, 71 (83.5%) patients required $ O_{2} $ support, but decreased to 7 (8.2%) post-rehabilitation. Barthel Index improved statistically from 44.82 ± 27.31 to 88.47 ± 17.56. Patient-based modulated rehabilitation programmes are highly effective in severe and critical COVID-19 complications, providing satisfactory well-being in daily living activities. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Inpatient rehabilitation |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neurological manifestations |7 (dpeaa)DE-He213 | |
650 | 4 | |a Patient outcome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Rehabilitation |7 (dpeaa)DE-He213 | |
700 | 1 | |a Yurdakul, Fatma Gül |e verfasserin |4 aut | |
700 | 1 | |a Acar Sivas, Filiz |e verfasserin |4 aut | |
700 | 1 | |a Kiliç, Zeynep |e verfasserin |4 aut | |
700 | 1 | |a Adigüzel, Emre |e verfasserin |4 aut | |
700 | 1 | |a Yaşar, Evren |e verfasserin |4 aut | |
700 | 1 | |a Bodur, Hatice |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 41(2021), 12 vom: 27. Sept., Seite 2167-2175 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2021 |g number:12 |g day:27 |g month:09 |g pages:2167-2175 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-021-05003-1 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.83 |q ASE |
951 | |a AR | ||
952 | |d 41 |j 2021 |e 12 |b 27 |c 09 |h 2167-2175 |